These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 10962573

  • 1. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.
    Clarke PA, Hostein I, Banerji U, Stefano FD, Maloney A, Walton M, Judson I, Workman P.
    Oncogene; 2000 Aug 24; 19(36):4125-33. PubMed ID: 10962573
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
    Banerji U, Walton M, Raynaud F, Grimshaw R, Kelland L, Valenti M, Judson I, Workman P.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 1):7023-32. PubMed ID: 16203796
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.
    Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA.
    Cancer Res; 2001 May 15; 61(10):4003-9. PubMed ID: 11358818
    [Abstract] [Full Text] [Related]

  • 4. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
    Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM.
    Cancer Chemother Pharmacol; 2005 Aug 15; 56(2):126-37. PubMed ID: 15841378
    [Abstract] [Full Text] [Related]

  • 5. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
    Beliakoff J, Bagatell R, Paine-Murrieta G, Taylor CW, Lykkesfeldt AE, Whitesell L.
    Clin Cancer Res; 2003 Oct 15; 9(13):4961-71. PubMed ID: 14581371
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV, Li Y, Rassidakis GZ, Martinez-Valdez H, Medeiros LJ, Younes A.
    Clin Cancer Res; 2006 Jan 15; 12(2):584-90. PubMed ID: 16428504
    [Abstract] [Full Text] [Related]

  • 7. Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo.
    Yin X, Zhang H, Burrows F, Zhang L, Shores CG.
    Clin Cancer Res; 2005 May 15; 11(10):3889-96. PubMed ID: 15897590
    [Abstract] [Full Text] [Related]

  • 8. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
    Bonvini P, Gastaldi T, Falini B, Rosolen A.
    Cancer Res; 2002 Mar 01; 62(5):1559-66. PubMed ID: 11888936
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
    Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, Ortiz KL, Sieck LK, Isaacs JS, Brechbiel MW, Mitchell JB, Neckers LM, Gius D.
    Cancer Res; 2003 Dec 15; 63(24):8984-95. PubMed ID: 14695217
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.
    Rahmani M, Yu C, Dai Y, Reese E, Ahmed W, Dent P, Grant S.
    Cancer Res; 2003 Dec 01; 63(23):8420-7. PubMed ID: 14679005
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation.
    Jeon YK, Park CH, Kim KY, Li YC, Kim J, Kim YA, Paik JH, Park BK, Kim CW, Kim YN.
    J Pathol; 2007 Oct 01; 213(2):170-9. PubMed ID: 17768706
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
    Price JT, Quinn JM, Sims NA, Vieusseux J, Waldeck K, Docherty SE, Myers D, Nakamura A, Waltham MC, Gillespie MT, Thompson EW.
    Cancer Res; 2005 Jun 01; 65(11):4929-38. PubMed ID: 15930315
    [Abstract] [Full Text] [Related]

  • 20. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
    Moser C, Lang SA, Stoeltzing O.
    Anticancer Res; 2009 Jun 01; 29(6):2031-42. PubMed ID: 19528462
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.